新闻源 财富源

2019年11月20日 星期三

人福医药(600079)公告正文

人福医药:2014年第一季度报告

公告日期:2014-04-30

人福医药集团股份公司
2014 年第一季度报告
    二〇一四年四月
                                   人福医药集团股份公司 2014 年第一季度报告
                        目 录第一章 重要提示 ........................................ 2第二章 公司主要财务数据和股东变化 ...................... 3第三章 重要事项 ........................................ 6第四章 附录 ........................................... 10
                                      人福医药集团股份公司 2014 年第一季度报告
                      第一章 重要提示
    (一)公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    (二)公司全体董事出席董事会审议季度报告。
    (三)公司负责人王学海、主管会计工作负责人吴亚君及会计机构负责人(会计主管人员)何华琴保证季度报告中财务报表的真实、准确、完整。
    公司负责人姓名                                          王学海
    主管会计工作负责人姓名                                  吴亚君
    会计机构负责人(会计主管人员)姓名                      何华琴
    (四)公司第一季度报告中的财务报表未经审计。
                                                         人福医药集团股份公司 2014 年第一季度报告
               第二章 公司主要财务数据和股东变化
    一、主要财务数据
                                                                       单位:元     币种:人民币
                                                                            本报告期末比上年
                               本报告期末                上年度末
                                                                              度末增减(%)
    总资产                        10,076,909,264.40          9,707,005,027.60                    3.81归属于上市公司股东的净
                               4,431,565,216.43          4,342,236,036.03                    2.06资产
                             年初至报告期末        上年初至上年报告期末
                                                                            比上年同期增减(%)
                               (1-3 月)                (1-3 月)经营活动产生的现金流量
                                157,808,713.47             -90,998,105.56                  不适用净额
                             年初至报告期末        上年初至上年报告期末
                                                                            比上年同期增减(%)
                               (1-3 月)                (1-3 月)
    营业收入                       1,606,578,185.99          1,378,134,897.35                   16.58归属于上市公司股东的净
                                 92,671,901.89             85,561,421.45                     8.31利润归属于上市公司股东的扣
                                 88,995,277.78             80,537,249.75                    10.50除非经常性损益的净利润
    加权平均净资产收益率(%)                   2.11                    2.79     减少 0.68 个百分点
    基本每股收益(元/股)                       0.18                    0.17                     5.88
    稀释每股收益(元/股)                       0.18                    0.17                     5.88扣除非经常性损益项目和金额:
                                                                       单位:元     币种:人民币
                                                                              本期金额
                              项目
                                                                              (1-3 月)
    非流动资产处置损益                                                                     -23,996.49计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国家
                                                                                     4,948,274.90政策规定、按照一定标准定额或定量持续享受的政府补助除外
    除上述各项之外的其他营业外收入和支出                                                  386,503.25
    所得税影响额                                                                          -435,398.27
    少数股东权益影响额(税后)                                                          -1,198,759.28
                              合计                                                   3,676,624.11
                                                                   人福医药集团股份公司 2014 年第一季度报告
    二、截至报告期末的股东总数、前十名股东、前十名无限售条件股东的持股情况表
                                                                                                    单位:股
    股东总数                                                                                             19,360 户
                                             前十名股东持股情况
                                                                           持有有限售条件    质押或冻结的
      股东名称(全称)          股东性质     持股比例(%)      持股总数
                                                                               股份数量          股份数量
    武汉当代科技产业集团股份有限    境内非国
                                                  17.07      90,287,061       32,432,757    质押 75,390,510
    公司                            有法人中国银行股份有限公司-嘉实研
                                   未知            3.02      15,986,558        1,030,000    无究精选股票型证券投资基金
    全国社保基金一零六组合             未知            2.60      13,747,977        2,717,035    无交通银行-博时新兴成长股票型
                                   未知            2.11      11,182,437               0     无证券投资基金财通基金-平安银行-平安信托
    平安财富创赢一期 55 号集合资       未知            1.89      10,000,000       10,000,000    无金信托计划中国人寿保险股份有限公司-传
    统-普通保险产品-005L-           未知            1.81       9,581,200               0     无CT001 沪中国光大银行股份有限公司-光
                                   未知            1.72       9,084,772               0     无大保德信量化核心证券投资中国光大银行股份有限公司-泰
                                   未知            1.70       9,000,000               0     无信先行策略开放式证券投资中国工商银行-广发聚富开放式
                                   未知            1.51       7,999,939               0     无证券投资基金泰康人寿保险股份有限公司-分
                                   未知            1.47       7,768,845               0     无红-个人分红-019L-FH002 沪
                                   前十名无限售条件流通股股东持股情况
                                                期末持有无限售条件流
             股东名称(全称)                                                      股份种类及数量
                                                     通股的数量
    武汉当代科技产业集团股份有限公司                           57,854,304      人民币普通股          57,854,304中国银行股份有限公司-嘉实研究精选股票型证
                                                           14,956,558      人民币普通股          14,956,558券投资基金
    交通银行-博时新兴成长股票型证券投资基金                   11,182,437      人民币普通股          11,182,437
    全国社保基金一零六组合                                     11,030,942      人民币普通股          11,030,942中国人寿保险股份有限公司-传统-普通保险产
                                                            9,581,200     人民币普通股            9,581,200品-005L-CT001 沪中国光大银行股份有限公司-光大保德信量化核
                                                            9,084,772      人民币普通股           9,084,772心证券投资中国光大银行股份有限公司-泰信先行策略开放
                                                            9,000,000      人民币普通股           9,000,000式证券投资
    中国工商银行-广发聚富开放式证券投资基金                    7,999,939      人民币普通股           7,999,939
                                                                人福医药集团股份公司 2014 年第一季度报告泰康人寿保险股份有限公司-分红-个人分红-
                                                        7,768,845       人民币普通股          7,768,845019L-FH002 沪
    武汉高科国有控股集团有限公司                            7,385,011       人民币普通股          7,385,011
                                             上述股东中持有本公司股份 5%(含 5%)以上法人股东为:武汉当
                                             代科技产业集团股份有限公司;
                                             公司前十名股东、前十名无限售条件股东中"中国银行股份有限公
                                             司-嘉实研究精选股票型证券投资基金"和"全国社保基金一零六上述股东关联关系或一致行动的说明
                                             组合"系嘉实基金管理有限公司控制下一致行动人;
                                             公司未知其他前十名股东之间、前十名无限售条件股东之间是否存
                                             在关联关系或属于《上市公司股东持股变动信息披露管理办法》规
                                             定的一致行动人。
                                                     人福医药集团股份公司 2014 年第一季度报告
                               第三章 重要事项
       一、公司主要会计报表项目、财务指标重大变动的情况及原因
    √适用 □不适用
    1、主要资产构成情况及财务数据比较分析
    截止 2014 年 3 月 31 日,公司总资产为 1,007,690.93 万元,比 2013 年底 970,700.50万元增加 36,990.43 万元,增长率为 3.81%。其中流动资产 543,240.23 万元,占总资产比例 53.91%,主要包括货币资金、存货、应收账款、其他应收款、预付账款;非流动性资产 464,450.70 万元,占总资产比例 46.09%,主要包括长期股权投资、固定资产、无形资产。
    (1)应付票据较期初增加 40.54%,主要系公司合理利用信用账期,采用银行承兑汇票付款所致;
    (2)应付利息较期初增加 49.36%,主要系按照权责发生制原则计提短期融资券、中期票据利息所致;
    (3)管理费用较上年同期增加 30.36%,主要系物价上涨导致的人工、日常开支增加所致;
    (4)资产减值损失较上年同期减少 56.08%,主要系上年度根据成本与市价孰低的原则计提了存货跌价准备,本期存货销售后存货跌价准备转回所致;
    (5)投资收益较上年同期减少 77.98%,主要系上期公司收到成本法核算的金融机构分配的上年度股利款;
    (6)营业外收入较上年同期减少 33.97%,主要系本期政府补贴收入较上期减少所致;
    (7)营业外支出较上年同期减少 75.92%,主要系前期基数较小所致。
    2、现金流量净额比较分析
    报告期内经营活动现金流量净额为 15,780.87 万元,较上年同期增加 24,880.68 万元,主要原因系销售回款额较上年同期有所上升所致;
       投资活动现金流量净额为-23,207.63 万元,较上年同期减少流出 24,869.16 万元,主要系上期支付了北京巴瑞医疗器械有限公司股权款尾款所致;
       筹资活动现金流量净额为 12,476.80 万元,较上年同期减少 35,904.05 万元,主要系上年度定向增发资金到位后,流动资金较为充裕,本期新增银行借款减少所致。
                                                   人福医药集团股份公司 2014 年第一季度报告
    二、重要事项进展情况及其影响和解决方案的分析说明
    √适用 □不适用
    1、经中国证监会审核无异议,并经公司 2011 年第 1 次临时股东大会审批授权,2011年 5 月 12 日公司董事会依据《武汉人福医药集团股份有限公司首期股权激励计划(草案修订稿)》规定,向符合授予条件的 73 名激励对象授予 21,857,950 股限制性股票。根据该激励计划,公司股权激励所涉限售股份将进行第三次解锁,第三次解锁股票数量为6,557,385 股,占公司股本总数的 1.24%,解锁日即上市流通日为 2014 年 5 月 13 日。
    2、经 2012 年第 1 次临时股东大会审批授权,中国银行间市场交易商协会于 2012 年9 月接受公司中期票据注册,注册金额为 12 亿元,注册额度有效期 2 年,公司可在注册有效期内分期发行。2012 年 11 月 8-9 日公司成功发行 2012 年度第一期中期票据(简称:12 人福 MTN1,代码:1282462),本次发行总额为 6 亿元人民币,期限 3 年,每张面值100 元,发行计息方式为附息式固定利率,收益率为 5.54%,起息日为 2012 年 11 月 12日,兑付方式为到期一次性还本付息,联席主承销商为中信银行股份有限公司、招商银行股份有限公司。截至本报告披露之日,该中期票据尚在存续期内。
    3、经 2013 年第 1 次临时股东大会审批授权,中国银行间市场交易商协会于 2013 年5 月接受公司短期融资券注册,注册金额为 8 亿元,注册额度有效期 2 年,公司可在注册有效期内分期发行。2013 年 6 月 19 日公司成功发行 2013 年度第一期短期融资券(简称:13 人福 CP001,代码 041355023),本次发行总额为 8 亿元人民币,期限 365 天,每张面值 100 元,发行利率为 5.4%,起息日为 2013 年 6 月 20 日,兑付方式为到期一次还本付息,联席主承销商为交通银行股份有限公司、民生银行股份有限公司。截至本报告披露之日,该短期融资券尚在存续期内。
    4、经中国证券监督管理委员会证监许可[2013]1081 号核准,公司于 2013 年 8 月向 4名特定对象非公开发行人民币普通股股票 35,333,586 股,每股发行价为 29.00 元,募集资金总额 1,024,673,994.00 元,扣除发行费用 39,341,272.92 元,实际募集资金净额为人民币985,332,721.08 元。上述资金到位情况业经大信会计师事务所(特殊普通合伙)验证,并出具大信验字[2013]第 2-00039 号《验资报告》。2013 年度使用的募集资金为 98,534.01万元,2014 年 1-3 月使用的募集资金为 0.01 万元,截至 2014 年 3 月 31 日,募集资金余额合计为 9.42 万元,差异 10.17 万元系利息收入。因募集资金投资项目“收购北京巴瑞医疗器械有限公司项目”已实施完毕、“武汉中原瑞德生物制品有限责任公司异地搬迁 GMP
                                                     人福医药集团股份公司 2014 年第一季度报告改造项目”已正式投入运营,截至本公告日,公司已注销全部募集资金专户,根据《上海证券交易所上市公司募集资金管理办法(2013 年修订)》,前述募集资金余额 9.42 万元转为公司流动资金。
    5、公司 2014 年第 2 次临时股东大会于 2014 年 4 月 11 日审议并通过了非公开发行股票的相关议案:本次非公开发行股票拟向包括武汉当代科技产业集团股份有限公司在内的5 名特定对象发行不超过 113,636,363 股(含 113,636,363 股)A 股股票,拟募集资金总额不超过 255,000 万元。有关事项详见公司于 2014 年 4 月 12 日在上海证券交易所网站(www.sse.com.cn)以及《上海证券报》、《证券时报》、《中国证券报》、《证券日报》上刊登的公告。目前,公司正在进行非公开发行的相关申报工作。
       三、公司及持股 5%以上的股东承诺事项履行情况
    √适用 □不适用
    1、公司在《首期股权激励计划(草案修订稿)》中明确,对于按照本股权激励计划授予的限制性股票,激励对象每一次申请标的股票解锁的公司业绩条件为:
    (1)解锁日上一年度公司的净利润不低于授予日前最近三个会计年度的平均水平且不得为负;
    (2)2011 年、2012 年、2013 年公司营业收入分别不低于 30 亿元、40 亿元、50 亿元;
    (3)2011 年、2012 年、2013 年公司净利润分别不低于 2.7 亿元、3.25 亿元、3.9 亿元;
    (4)2011 年、2012 年、2013 年公司加权平均净资产收益率分别不低于 8%。
    若达到激励计划规定的解锁条件,激励对象可分三次申请解锁,分别自授予日起的12 个月后、24 个月后、36 个月后各申请解锁授予限制性股票总量的 40%、30%、30%。
    2、公司第一大股东当代科技在股权分置改革方案中承诺:
    (1)持有的非流通股股份自获得上市流通权之日起在 60 个月内不上市交易或转让;
    (2)在第(1)项承诺期满后,每年通过上海证券交易所挂牌交易出售股份数量占所持股份数的比例不超过 15%;
    (3)不以低于 2005 年 6 月 17 日前 30 个交易日算术平均值的 185%(6.00 元)的价格通过上海证券交易所挂牌交易出售股票。人福医药集团股份公司 2014 年第一季度报告
                                第四章 附录
                                合并资产负债表
                                 2014 年 3 月 31 日
    编制单位:人福医药集团股份公司                  单位:元 币种:人民币 审计类型:未经审计
                     项目                          期末余额              年初余额流动资产:
    货币资金                                      1,257,462,078.86          1,206,126,636.75
    结算备付金
    拆出资金
    交易性金融资产
    应收票据                                        244,728,430.35            311,254,567.05
    应收账款                                      2,105,485,939.29          1,901,316,959.17
    预付款项                                        448,660,327.61            520,048,015.54
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                      480,809,007.42           464,379,258.23
    买入返售金融资产
    存货                                            895,256,519.81           910,104,703.56
    一年内到期的非流动资产
    其他流动资产
    流动资产合计                                5,432,402,303.34          5,313,230,140.30非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                    601,387,602.34           570,430,847.17
    投资性房地产
    固定资产                                      1,928,906,635.34          1,629,814,955.52
    在建工程                                        435,176,523.59            559,731,515.21
    工程物资                                        166,041,155.31            143,735,953.45
    固定资产清理                                     26,629,096.10
    生产性生物资产
    油气资产
    无形资产                                        574,703,666.94           579,811,142.02
    开发支出                                         36,697,279.34            34,675,772.34
    商誉                                            847,497,856.24           847,497,856.24
    长期待摊费用                                      9,519,354.76             9,937,830.29
    递延所得税资产                                   17,947,791.10            18,139,015.06
    其他非流动资产
    非流动资产合计                              4,644,506,961.06          4,393,774,887.30
      资产总计                                 10,076,909,264.40          9,707,005,027.60
                                                       人福医药集团股份公司 2014 年第一季度报告流动负债:
    短期借款                                          1,308,702,906.33          1,194,315,049.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                                            88,150,178.67             62,721,257.74
    应付账款                                           723,865,617.26            687,339,803.79
    预收款项                                           116,178,652.25            100,423,380.37
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                                         9,907,067.38             11,280,615.41
    应交税费                                           113,501,028.37            138,547,104.41
    应付利息                                            50,181,058.23             33,596,885.21
    应付股利                                            10,788,343.66             10,788,343.66
    其他应付款                                         326,622,570.32            290,710,567.75
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债                              110,737,800.00            109,744,200.00
    其他流动负债                                        800,000,000.00            800,000,000.00
    流动负债合计                                    3,658,635,222.47          3,439,467,207.34非流动负债:
    长期借款                                           506,843,205.00            458,870,491.00
    应付债券                                           598,992,289.53            598,849,373.35
    长期应付款
    专项应付款                                            7,522,794.35              7,902,335.83
    预计负债
    递延所得税负债
    其他非流动负债                                      140,168,537.06            121,569,557.67
    非流动负债合计                                  1,253,526,825.94          1,187,191,757.85
      负债合计                                      4,912,162,048.41          4,626,658,965.19所有者权益(或股东权益):
    实收资本(或股本)                                  528,777,222.00            528,777,222.00
    资本公积                                          2,043,985,947.16          2,047,236,000.43
    减:库存股
    专项储备
    盈余公积                                           167,208,909.80            167,208,909.80
    一般风险准备
    未分配利润                                        1,691,122,626.39       1,598,450,724.50
    外币报表折算差额                                        470,511.08             563,179.30
    归属于母公司所有者权益合计                        4,431,565,216.43       4,342,236,036.03
    少数股东权益                                        733,181,999.56         738,110,026.38
      所有者权益合计                                5,164,747,215.99       5,080,346,062.41
      负债和所有者权益总计                        10,076,909,264.40        9,707,005,027.60
    公司法定代表人: 王学海         主管会计工作负责人:吴亚君             会计机构负责人:何华琴
                                                        人福医药集团股份公司 2014 年第一季度报告
                                 母公司资产负债表
                                  2014 年 3 月 31 日
    编制单位:人福医药集团股份公司                   单位:元     币种:人民币     审计类型:未经审计
                     项目                          期末余额                    年初余额流动资产:
        货币资金                                       719,247,191.80           731,920,872.26
        交易性金融资产
        应收票据                                        23,000,000.00
        应收账款
        预付款项                                        37,030,983.38             32,564,713.08
        应收利息
        应收股利
        其他应收款                                 1,623,475,841.10            1,636,968,030.44
        存货                                              200,181.93                 222,653.62
        一年内到期的非流动资产
        其他流动资产
             流动资产合计                          2,402,954,198.21            2,401,676,269.40非流动资产:
        可供出售金融资产
        持有至到期投资
        长期应收款
        长期股权投资                               3,073,893,140.23            3,006,277,088.61
        投资性房地产
        固定资产                                       145,424,462.18           145,205,507.77
        在建工程                                         1,659,802.27                452,958.00
        工程物资
        固定资产清理
        生产性生物资产
        油气资产
        无形资产                                         1,275,867.74              1,320,902.57
        开发支出
        商誉
        长期待摊费用
        递延所得税资产
        其他非流动资产
             非流动资产合计                        3,222,253,272.42            3,153,256,456.95
                 资产总计                          5,625,207,470.63            5,554,932,726.35
                                                      人福医药集团股份公司 2014 年第一季度报告流动负债:
        短期借款                                     306,100,000.00           253,000,000.00
        交易性金融负债
        应付票据
        应付账款                                      23,011,587.56             22,691,598.13
        预收款项
        应付职工薪酬                                    123,991.62                 145,676.13
        应交税费                                       2,148,115.56             21,218,157.79
        应付利息                                      48,037,131.50             31,269,960.71
        应付股利                                       8,680,792.09              8,680,792.09
        其他应付款                                   126,623,750.32             79,048,993.22
        一年内到期的非流动负债
        其他流动负债                                 800,000,000.00           800,000,000.00
             流动负债合计                          1,314,725,368.65          1,216,055,178.07非流动负债:
        长期借款
        应付债券                                     598,992,289.53           598,849,373.35
        长期应付款
        专项应付款                                     6,036,477.56              6,198,877.56
        预计负债
        递延所得税负债
        其他非流动负债
             非流动负债合计                          605,028,767.09           605,048,250.91
                 负债合计                          1,919,754,135.74          1,821,103,428.98所有者权益(或股东权益):
        实收资本(或股本)                           528,777,222.00           528,777,222.00
        资本公积                                   2,130,163,428.27          2,126,625,081.21
        减:库存股
        专项储备
        盈余公积                                     167,208,909.80           167,208,909.80
        一般风险准备
        未分配利润                                   879,303,774.82           911,218,084.36
    所有者权益(或股东权益)合计                       3,705,453,334.89          3,733,829,297.37
                 负债和所有者权益(或股东权
                                                   5,625,207,470.63          5,554,932,726.35益)总计
    公司法定代表人: 王学海           主管会计工作负责人:吴亚君            会计机构负责人:何华琴
                                                              人福医药集团股份公司 2014 年第一季度报告
                                          合并利润表
                                          2014 年 1-3 月
    编制单位:人福医药集团股份公司                        单位:元 币种:人民币 审计类型:未经审计
                       项目                                本期金额                 上期金额
    一、营业总收入                                            1,606,578,185.99         1,378,134,897.35
    其中:营业收入                                          1,606,578,185.99         1,378,134,897.35
      利息收入
      已赚保费
      手续费及佣金收入
    二、营业总成本                                            1,434,619,152.85         1,221,980,655.00
    其中:营业成本                                           948,756,280.87            782,493,920.48
      利息支出
      手续费及佣金支出
      退保金
      赔付支出净额
      提取保险合同准备金净额
      保单红利支出
      分保费用
      营业税金及附加                                         12,814,925.41             10,046,244.46
      销售费用                                              270,149,009.30            251,602,117.81
      管理费用                                              157,110,455.98            120,517,590.04
      财务费用                                               39,139,114.39             42,179,937.07
      资产减值损失                                            6,649,366.90             15,140,845.14
    加:公允价值变动收益(损失以“-”号填列)
    投资收益(损失以“-”号填列)                           1,155,173.64              5,246,205.68
      其中:对联营企业和合营企业的投资收益                      555,173.65              4,204,436.64
    汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                         173,114,206.78            161,400,448.03
    加:营业外收入                                             5,610,586.22              8,496,925.46
    减:营业外支出                                               299,804.56              1,245,032.72
    其中:非流动资产处置损失                                     -23,996.49               359,940.97
    四、利润总额(亏损总额以“-”号填列)                     178,424,988.44            168,652,340.77
    减:所得税费用                                            41,720,529.69             38,405,641.55
    五、净利润(净亏损以“-”号填列)                         136,704,458.75            130,246,699.22
                                                        人福医药集团股份公司 2014 年第一季度报告
    归属于母公司所有者的净利润                           92,671,901.89            85,561,421.45
    少数股东损益                                         44,032,556.86            44,685,277.77六、每股收益:
    (一)基本每股收益                                            0.18                      0.17
    (二)稀释每股收益                                            0.18                      0.17
    七、其他综合收益                                         -240,070.72              -333,410.03
    八、综合收益总额                                      136,464,388.03           129,913,289.19
    归属于母公司所有者的综合收益总额                     92,980,815.19            86,126,552.08
    归属于少数股东的综合收益总额                         43,483,572.84            43,786,737.11
    公司法定代表人: 王学海            主管会计工作负责人:吴亚君             会计机构负责人:何华琴
                                                            人福医药集团股份公司 2014 年第一季度报告
                                         母公司利润表
                                         2014 年 1-3 月
    编制单位:人福医药集团股份公司                       单位:元 币种:人民币 审计类型:未经审计
                     项目                                 本期金额                上期金额一、营业收入
    减:营业成本
    营业税金及附加
    销售费用
    管理费用                                                19,998,230.18            16,296,771.55
    财务费用                                                14,035,503.73            24,743,287.21
    资产减值损失                                              143,795.73              2,138,241.82
    加:公允价值变动收益(损失以“-”号填列)
    投资收益(损失以“-”号填列)                           1,283,220.10           151,148,626.65
    其中:对联营企业和合营企业的投资收益                     683,220.10              3,832,651.67
    二、营业利润(亏损以“-”号填列)                         -32,894,309.54           107,970,326.07
    加:营业外收入                                              980,000.00                746,685.64
    减:营业外支出                                                                        530,000.00
    其中:非流动资产处置损失                                                             355,416.67
    三、利润总额(亏损总额以“-”号填列)                     -31,914,309.54           108,187,011.71
    减:所得税费用
    四、净利润(净亏损以“-”号填列)                         -31,914,309.54           108,187,011.71五、每股收益:
    (一)基本每股收益
    (二)稀释每股收益
    六、其他综合收益                                              401,581.52                541,824.18
    七、综合收益总额                                           -31,512,728.02           108,728,835.89
    公司法定代表人: 王学海           主管会计工作负责人:吴亚君                  会计机构负责人:何华琴
                                                          人福医药集团股份公司 2014 年第一季度报告
                                   合并现金流量表
                                     2014 年 1-3 月
    编制单位:人福医药集团股份公司                     单位:元 币种:人民币     审计类型:未经审计
                     项目                              本期金额                  上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                         1,642,967,021.04          1,311,584,016.65
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                          1,914,937.95                 366,205.01
    收到其他与经营活动有关的现金                          189,418,073.08            102,381,234.85
    经营活动现金流入小计                                1,834,300,032.07          1,414,331,456.51
    购买商品、接受劳务支付的现金                          945,312,859.30            859,341,417.77
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现金                        153,891,104.32            119,851,105.44
    支付的各项税费                                        195,131,788.88            166,480,930.41
    支付其他与经营活动有关的现金                          382,155,566.10            359,656,108.45
    经营活动现金流出小计                                1,676,491,318.60          1,505,329,562.07
    经营活动产生的现金流量净额                          157,808,713.47             -90,998,105.56二、投资活动产生的现金流量:
    收回投资收到的现金                                                                 1,000,000.00
    取得投资收益收到的现金                                    600,000.00               2,046,212.90
    处置固定资产、无形资产和其他长期资产收回
                                                            100,200.00                 694,765.00的现金净额
                                                       人福医药集团股份公司 2014 年第一季度报告
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金                          2,983,181.45              3,811,084.15
    投资活动现金流入小计                                 3,683,381.45              7,552,062.05
    购建固定资产、无形资产和其他长期资产支付
                                                      184,146,284.13           205,732,116.29的现金
    投资支付的现金                                       51,613,394.72           282,587,799.49
    质押贷款净增加额
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                               235,759,678.85           488,319,915.78
    投资活动产生的现金流量净额                       -232,076,297.40           -480,767,853.73三、筹资活动产生的现金流量:
    吸收投资收到的现金                                                              2,250,000.00
    其中:子公司吸收少数股东投资收到的现金                                          2,250,000.00
    取得借款收到的现金                                  460,148,009.18           834,350,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金                         23,060,389.22             30,000,000.00
    筹资活动现金流入小计                               483,208,398.40           866,600,000.00
    偿还债务支付的现金                                  298,867,971.85           302,350,000.00
    分配股利、利润或偿付利息支付的现金                   59,044,394.23             78,423,213.74
    其中:子公司支付给少数股东的股利、利润               27,200,000.00             27,468,500.00
    支付其他与筹资活动有关的现金                           528,000.00               2,018,287.91
    筹资活动现金流出小计                               358,440,366.08           382,791,501.65
    筹资活动产生的现金流量净额                        124,768,032.32           483,808,498.35
    四、汇率变动对现金及现金等价物的影响                     834,993.72                -375,730.44
    五、现金及现金等价物净增加额                           51,335,442.11            -88,333,191.38
    加:期初现金及现金等价物余额                      1,125,510,462.26           871,047,794.56
    六、期末现金及现金等价物余额                        1,176,845,904.37           782,714,603.18
    公司法定代表人: 王学海           主管会计工作负责人:吴亚君             会计机构负责人:何华琴
                                                            人福医药集团股份公司 2014 年第一季度报告
                                   母公司现金流量表
                                      2014 年 1-3 月
    编制单位:人福医药集团股份公司                     单位:元     币种:人民币      审计类型:未经审计
                    项目                               本期金额                    上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金
    收到的税费返还
    收到其他与经营活动有关的现金                          140,753,593.30                93,273,822.45
    经营活动现金流入小计                                140,753,593.30                93,273,822.45
    购买商品、接受劳务支付的现金                              933,726.26                   238,316.70
    支付给职工以及为职工支付的现金                          5,247,601.33                 6,917,480.08
    支付的各项税费                                         19,586,147.63                 1,334,594.81
    支付其他与经营活动有关的现金                          105,382,036.16                73,624,957.74
    经营活动现金流出小计                                131,149,511.38                82,115,349.33
      经营活动产生的现金流量净额                          9,604,081.92                11,158,473.12二、投资活动产生的现金流量:
    收回投资收到的现金
    取得投资收益收到的现金                                      600,000.00               1,000,000.00
    处置固定资产、无形资产和其他长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金                               2,372,494.92              2,375,282.14
    投资活动现金流入小计                                     2,972,494.92              3,375,282.14
    购建固定资产、无形资产和其他长期资产支付
                                                             4,728,555.72              6,192,550.98的现金
    投资支付的现金                                            66,944,644.72           283,077,799.49
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                                 71,673,200.44               289,270,350.47
      投资活动产生的现金流量净额                        -68,700,705.52              -285,895,068.33三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金                                    110,000,000.00              396,900,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金                            2,000,000.00
    筹资活动现金流入小计                                112,000,000.00              396,900,000.00
    偿还债务支付的现金                                     56,900,000.00               76,900,000.00
    分配股利、利润或偿付利息支付的现金                      8,149,056.86               12,472,353.17
    支付其他与筹资活动有关的现金                              528,000.00                2,000,000.00
    筹资活动现金流出小计                                 65,577,056.86               91,372,353.17
      筹资活动产生的现金流量净额                         46,422,943.14              305,527,646.83四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额                            -12,673,680.46               30,791,051.62
    加:期初现金及现金等价物余额                          651,304,697.77              440,368,538.08
    六、期末现金及现金等价物余额                            638,631,017.31              471,159,589.70
    公司法定代表人: 王学海          主管会计工作负责人:吴亚君                   会计机构负责人:何华琴